Last reviewed · How we verify
MYL-1701P, a proposed biosimilar to Eylea
MYL-1701P is a biosimilar to aflibercept that binds vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit pathological neovascularization in the eye.
MYL-1701P is a biosimilar to aflibercept that binds vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit pathological neovascularization in the eye. Used for Neovascular (wet) age-related macular degeneration, Retinal vein occlusion, Diabetic macular edema.
At a glance
| Generic name | MYL-1701P, a proposed biosimilar to Eylea |
|---|---|
| Sponsor | Mylan Pharmaceuticals Inc |
| Drug class | Monoclonal antibody (fusion protein) / VEGF inhibitor / Biosimilar |
| Target | VEGF-A, VEGF-B, PlGF (vascular endothelial growth factor and placental growth factor) |
| Modality | Biologic |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
As a biosimilar to Eylea (aflibercept), MYL-1701P is a recombinant fusion protein that acts as a VEGF trap, sequestering VEGF-A, VEGF-B, and PlGF to prevent their interaction with endothelial growth factor receptors. This mechanism reduces abnormal blood vessel growth and vascular permeability in retinal diseases. The biosimilar is designed to have comparable efficacy and safety to the reference product in treating neovascular age-related macular degeneration and other retinal conditions.
Approved indications
- Neovascular (wet) age-related macular degeneration
- Retinal vein occlusion
- Diabetic macular edema
Common side effects
- Conjunctival hemorrhage
- Eye pain
- Floaters
- Intraocular pressure elevation
- Endophthalmitis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: